Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The bone metastasis market trends are a mix of intricate factors characterized by medical research growth, evolving treatment processes, and the improved diagnostic techniques. An example of these patterns is the escalating global prevalence rate of bone metastasis cases which is mainly due to increased primary cancers like breast, prostate and lung ones. Better understanding and detection of cancer along with increasing survival rates and enhanced diagnostics has spurred an awareness of bone metastases. This means that it is necessary to recognize that there are issues affecting patients with bone metastatic disease such as skeletal related events as well as poor quality life.
Diagnosis has been greatly improved through advancement in diagnostic tools like PET (positron emission tomography) scan and MRI (magnetic resonance imaging). Biomarkers; Liquid biopsies have also become popular as a way in which cancer spread to the bones can be determined. Thus, early detection allows clinicians to diagnose on time so that different therapeutic strategies may be tailored for maximum effect on patients.
The big pharmaceutical companies have interests in oncology leading to various options for treating bone metastasis including targeted therapies, immunotherapies etc. These include medications known as bone modifying agents namely RANK ligand inhibitors or bisphosphonates used frequently for managing osteologic complications associated with bony secondary tumors. There are ongoing studies focusing on new therapeutic targets such as immune checkpoint inhibitors or targeted kinases players aimed at bettering treatment options available. Such behavior reveals that specific challenges for curing osseous secondaries need to be addressed alongside a view towards enhancing overall prognosis of patients.
Personalized medicine is now infiltrating into the bone sector concerning the trendsetters thereof-bone metastasis patients. In conclusion, doctors have recognized this fact leading them into developing those treatments which tend to address patient’s gene composition or molecular characteristics plus cell properties. With precision medicine finally here, health care professionals can better pick drugs that would work best while minimally harming the patient. This new approach in which we deal with bone metastasis will mean that there will be more targeted therapy and fewer side effects.
A collective effort by healthcare providers, academic researchers and drug firms are reshaping the face of bone metastasis care. This is possible through establishing a multidisciplinary tumor board which includes experts from different fields of medicine to ensure that there is comprehensive and organized patient handling. By so doing, these cooperative activities also help in coming up with studies targeting on better comprehension of bone biology and treatment strategies for cancer secondary to bones.
Telemedicine and digital health technologies are increasingly becoming important aspects of providing care for patients with bone metastasis especially during follow-up or supportive care settings. Irrespective of where one stays, such platforms can remotely link them to their doctors, monitor their condition besides rendering supportive services hence increasing access channel to persons having osseous secondaries. Therefore, this inclination accords with the rapid adoption of electronic medical systems at large while they promise a customer-oriented means towards addressing the intricacies related to skeletal secondaries.
The combination between evaluation procedures for bone density and prevention initiatives has assumed greater significance as far as management of bone metastasis is concerned. In recognition of the necessity for maintaining bony integrity, improving skeletal complications’ outcomes providers include this aspect into cancer patients’ global care plans. Thus, trend implies taking action before suffering from skeletogenic secondary types in order to enhance quality life standards.
Bone Metastasis Market Highlights:
Bone Metastasis Market Overview
The Bone Metastasis Market size is expected to reach USD 17.5 Billion by 2032 at 9.4% CAGR during the forecast period 2023-2032. The spread of malignant cells from their initial place to a bone is known as bone metastasis.
Bone metastases can occur in any type of malignancy. Breast cancer and prostate cancer, on the other hand, are thought to be frequently linked to the disease. The medical issue affects the spine, pelvis, and thighs frequently. Some of the most prevalent symptoms of the condition include urinary incontinence, bowel incontinence, and hypercalcemia. During the projection period, the rising prevalence of bone metastasis is expected to be a major driver of market growth. When cancer cells break off from a primary tumor that is located elsewhere in the body, bone metastasis, often known as bone Mets, occurs.
These cancer cells migrate to a portion of the bone through the bloodstream or the lymph system and become metastatic cancer cells. This is not the same as a primary bone tumor, which begins in the bone. Osteoclasts cause a bone breakdown in the absence of fresh bone formation, weakening the bones. Because of the benefits given by minimally invasive procedures over traditional treatment procedures, there has been a huge growth in demand for them.
Fewer operating complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced post-surgical care, and faster recovery are all advantages of minimally invasive procedures. There are various advanced techniques used in minimally invasive treatments to detect and treat a variety of disorders, including cancer.
ZetaMet technology was granted a breakthrough device designation by the FDA's Centers for Devices and Radiological Health in December 2021 for use in the treatment of Bone Metastasis and osteologic treatments. The company, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. in October 2020 to provide more upside potential in areas like Infectious Diseases and Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1: Bone Metastasis Market Share, by Region
Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation
Bone Metastasis Market Segmentation
The bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the bone metastasis market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.
On the basis of diagnosis, the bone metastasis market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.
On the basis of the treatment, the bone metastasis market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.
On the basis of end-user, the bone metastasis market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.
Bone Metastasis Market Regional Analysis
America dominates the bone metastasis market. This can be attributed to the presence of a well-developed healthcare sector, the increasing prevalence of breast cancer, and increasing healthcare sector within the region. Moreover, the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the regional market growth.
Europe is the second in the bone metastasis market owing to the availability of funds for research and a huge patient population. According to the Cancer Research U.K., approximately 55,122 new cases of invasive breast cancer were reported in 2015. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe leads the regional market due to the presence of developed economies within the region.
Asia Pacific is projected to be the fastest growing region in the bone metastasis market. The presence of developing economies such as India and China, a developing healthcare sector, and the growing prevalence of cancer within the region drive the market growth in the region. Moreover, favorable government policies and increasing penetration of key market players within the region fuel the market growth.
The Middle East and Africa holds the least share in the bone metastasis market, owing to the presence of poor economies, stringent government policies, and lack of healthcare services, especially within the African region. A majority of the market of bone metastasis in the Middle East and Africa is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure by developed economies such as Saudi Arabia, Kuwait, Dubai, and others within the region.
Recent Development
ZetaMet technology was granted a breakthrough device designation by the FDA's Centers for Devices and Radiological Health in December 2021 for use in the treatment of Bone Metastasis and osteologic treatments. The company, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. in October 2020 to provide more upside potential in areas like Infectious Diseases and Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Key Players in the Bone Metastasis Market
The key players in the bone metastasis market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Pharmalucence Inc. (England)
- Koninklijke Philips N.V. (the Netherlands)
- GENERAL ELECTRIC (U.S.)
- Siemens AG (Germany)
- TOSHIBA CORPORATION (Japan)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
